PL2697207T3 - Pochodne 3-(2-arylocykloalkenylometylo)oksazolidyn-2-onu jako inhibitory białka transportującego estry cholesterolu (cetp) - Google Patents

Pochodne 3-(2-arylocykloalkenylometylo)oksazolidyn-2-onu jako inhibitory białka transportującego estry cholesterolu (cetp)

Info

Publication number
PL2697207T3
PL2697207T3 PL12770951T PL12770951T PL2697207T3 PL 2697207 T3 PL2697207 T3 PL 2697207T3 PL 12770951 T PL12770951 T PL 12770951T PL 12770951 T PL12770951 T PL 12770951T PL 2697207 T3 PL2697207 T3 PL 2697207T3
Authority
PL
Poland
Prior art keywords
cycloalkenylmethyl
cetp
oxazolidin
inhibitors
aryl
Prior art date
Application number
PL12770951T
Other languages
English (en)
Inventor
Seohee Lee
Jungtaek Oh
Jaekwang Lee
Jaewon Lee
Suyeal Bae
Nina Ha
Sera Lee
Original Assignee
Chong Kun Dang Pharmaceutical Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chong Kun Dang Pharmaceutical Corp. filed Critical Chong Kun Dang Pharmaceutical Corp.
Publication of PL2697207T3 publication Critical patent/PL2697207T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL12770951T 2011-04-12 2012-04-12 Pochodne 3-(2-arylocykloalkenylometylo)oksazolidyn-2-onu jako inhibitory białka transportującego estry cholesterolu (cetp) PL2697207T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20110033943 2011-04-12
EP12770951.7A EP2697207B1 (en) 2011-04-12 2012-04-12 3-(2-aryl-cycloalkenylmethyl)-oxazolidin-2-one derivatives as cholesterol ester transfer protein (cetp) inhibitors

Publications (1)

Publication Number Publication Date
PL2697207T3 true PL2697207T3 (pl) 2017-08-31

Family

ID=47009830

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12770951T PL2697207T3 (pl) 2011-04-12 2012-04-12 Pochodne 3-(2-arylocykloalkenylometylo)oksazolidyn-2-onu jako inhibitory białka transportującego estry cholesterolu (cetp)

Country Status (18)

Country Link
US (1) US9371294B2 (pl)
EP (1) EP2697207B1 (pl)
JP (1) JP5820056B2 (pl)
KR (1) KR101442644B1 (pl)
CN (1) CN103502226B (pl)
AU (1) AU2012243583B2 (pl)
BR (1) BR112013026280A2 (pl)
CA (1) CA2829676C (pl)
DK (1) DK2697207T3 (pl)
ES (1) ES2617221T3 (pl)
HR (1) HRP20170422T1 (pl)
HU (1) HUE032075T2 (pl)
MX (1) MX342104B (pl)
PH (1) PH12013501829A1 (pl)
PL (1) PL2697207T3 (pl)
PT (1) PT2697207T (pl)
RU (1) RU2597266C2 (pl)
WO (1) WO2012141487A2 (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014213125B2 (en) * 2013-01-31 2016-06-02 Chong Kun Dang Pharmaceutical Corp. Biaryl- or heterocyclic biaryl-substituted cyclohexene derivative compounds as CETP inhibitors
US10547785B2 (en) * 2015-03-31 2020-01-28 Huawei Technologies Co., Ltd. Photographing method including image registration based on reference image, shake information, and a motion vector table
CN107304174B (zh) * 2016-04-21 2019-05-10 沈阳药科大学 N,n-双取代环烯基甲胺类衍生物及其制备方法和应用
AR109596A1 (es) 2016-09-09 2018-12-26 Incyte Corp Compuestos pirazolopiridina y sus usos
US20180072718A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine compounds and uses thereof
US20180072741A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
WO2018152220A1 (en) 2017-02-15 2018-08-23 Incyte Corporation Pyrazolopyridine compounds and uses thereof
US10722495B2 (en) 2017-09-08 2020-07-28 Incyte Corporation Cyanoindazole compounds and uses thereof
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
DK3755703T3 (da) 2018-02-20 2022-06-27 Incyte Corp N-(phenyl)-2-(phenyl)pyrimidin-4-carboxamidderivater og relaterede forbindelser som hpk1-inhibitorer til behandling af kræft
US10752635B2 (en) 2018-02-20 2020-08-25 Incyte Corporation Indazole compounds and uses thereof
CR20200464A (es) 2018-03-08 2021-04-14 Incyte Corp Compuestos diólicos de aminopirazina como inhibidores de pi3k-y
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
CN110759860B (zh) * 2018-07-27 2022-10-14 江苏瑞科医药科技有限公司 一种3-甲酸甲酯-4-甲氧基-5-氰基吡啶的制备方法
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
WO2020068729A1 (en) 2018-09-25 2020-04-02 Incyte Corporation Pyrazolo[4,3-d]pyrimidine compounds as alk2 abd/or fgfr modulators
KR20220059480A (ko) 2019-08-06 2022-05-10 인사이트 코포레이션 고체 형태의 hpk1 억제제

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5929094A (en) 1996-10-25 1999-07-27 Merck & Co., Inc. Heteroaryl spiroethercycloalkyl tachykinin receptor antagonists
JP2894445B2 (ja) 1997-02-12 1999-05-24 日本たばこ産業株式会社 Cetp活性阻害剤として有効な化合物
CA2445623A1 (en) 2001-04-30 2002-11-07 Pfizer Products Inc. Methods for preparing cetp inhibitors
DOP2005000123A (es) * 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
US8865707B2 (en) * 2005-12-30 2014-10-21 Merck Sharp & Dohme Corp. Cholesteryl ester transfer protein inhibitors
WO2007081569A2 (en) * 2005-12-30 2007-07-19 Merck & Co., Inc. Cetp inhibitors
JP5040036B2 (ja) 2005-12-30 2012-10-03 メルク・シャープ・エンド・ドーム・コーポレイション Cetp阻害剤として有用な1,3−オキサゾリジン−2−オン誘導体
CA2681628C (en) * 2007-03-16 2016-10-18 Concert Pharmaceuticals, Inc. Inhibitors of cholesterol ester transfer protein
GB2463788B (en) 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
US8354454B2 (en) * 2008-10-01 2013-01-15 Merck Sharp & Dohme Corp. Prodrugs of oxazolidinone CETP inhibitors

Also Published As

Publication number Publication date
US9371294B2 (en) 2016-06-21
KR101442644B1 (ko) 2014-09-19
EP2697207A2 (en) 2014-02-19
CN103502226B (zh) 2015-08-19
ES2617221T3 (es) 2017-06-15
RU2597266C2 (ru) 2016-09-10
JP5820056B2 (ja) 2015-11-24
AU2012243583A1 (en) 2013-10-03
CA2829676A1 (en) 2012-10-18
EP2697207B1 (en) 2016-12-14
WO2012141487A3 (en) 2013-01-10
US20150119376A2 (en) 2015-04-30
RU2013145418A (ru) 2015-05-20
MX342104B (es) 2016-09-13
PH12013501829A1 (en) 2015-10-23
PT2697207T (pt) 2017-02-14
US20140031335A1 (en) 2014-01-30
HRP20170422T1 (hr) 2017-06-16
JP2014510786A (ja) 2014-05-01
EP2697207A4 (en) 2014-11-19
MX2013011855A (es) 2013-11-01
DK2697207T3 (en) 2017-03-27
HUE032075T2 (en) 2017-08-28
CN103502226A (zh) 2014-01-08
BR112013026280A2 (pt) 2024-04-30
KR20120116362A (ko) 2012-10-22
CA2829676C (en) 2017-08-22
WO2012141487A2 (en) 2012-10-18
AU2012243583B2 (en) 2015-10-22
NZ615071A (en) 2015-05-29

Similar Documents

Publication Publication Date Title
PT2697207T (pt) Derivados de 3-(2-aril-cicloalcenilmetil)-oxazolidin-2-ona como inibidores da proteína de transferência de ésteres de colesterol (cetp)
EP2699293B8 (en) Autoinjector apparatus
ZA201306175B (en) Isoxazole derivatives
IL232139A0 (en) A process for the preparation of quinoline hist
AP2013007043A0 (en) Novel heterocyclic derivatives
IL247642A0 (en) History of isoxazole
AU338702S (en) Serving tray
EP2799376A4 (en) Arced-passage transfer apparatus
EP2669574A4 (en) COMBUSTION DEVICE FOR HEATING AN OVEN
EP2744788A4 (en) BENZOPIPERAZINE DERIVATIVES AS CETP INHIBITORS
LU91844B1 (en) Charging device for shaft furnace
EP3095777A4 (en) Linezolid intermediate and method for synthesizing linezolid
EP2673387A4 (en) Direct smelting process
KR101243876B9 (ko) 기판 처리 장치
AP2014007697A0 (en) Quinoline derivatives as PDE1OA enzyme inhibitors
PL2482017T3 (pl) Instalacja do suszenia produktów
HU4188U (en) Arrangement for developing improved effected biogas
ZA201401460B (en) Method for cloning microbial genes
EM19585960002S (pl) Urządzenia grzewcze (część - )
EM19312470001S (pl) Urządzenia grzewcze
EM19366180001S (pl) Urządzenia grzewcze
EM19585960001S (pl) Urządzenia grzewcze
AU2011901788A0 (en) Heating apparatus
AU2011900418A0 (en) Heating Apparatus
AU2011904413A0 (en) Heating Apparatus